Monoclonal Antibody to Receptor Interacting Serine Threonine Kinase 1 (RIPK1)
| Code | Size | Price |
|---|
| MAE640Hu22-20ul | 20ul | £92.00 |
Quantity:
| MAE640Hu22-100ul | 100ul | £173.00 |
Quantity:
| MAE640Hu22-200ul | 200ul | £234.00 |
Quantity:
| MAE640Hu22-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
RIP; Receptor-Interacting Protein; Cell death protein RIP; Serine/threonine-protein kinase RIP
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Receptor Interacting Serine Threonine Kinase 1
Potency (Clone Number):
C4
Reactivity:
Po;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-3ug/mL
Immunohistochemistry: 5-30ug/mL
Immunocytochemistry: 5-30ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-30ug/mL
Immunocytochemistry: 5-30ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Receptor Interacting Serine Threonine Kinase 1 (RIPK1) | RPE640Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||